Amyris has shipped its first batch of sustainable fermentation-derived cannabinoid (CBD) to its partner, Lavvan. Amyris will send its second shipment in the first half of 2020, per the firm.
The fermentation process reportedly boosts the sustainability of the ingredient by removing agricultural inputs while also supporting consistency of product and reduced costs.
Amyris is targeting an additional 22 molecules for commercialization.
Meanwhile, Biossance, Amyris' consumer brand, now achieves 50% of its revenue from its brand-owned website, while also driving growth through its partnership with Sephora.
"We are very pleased to end 2019 with strong operational performance and business momentum," said John Melo, President and CEO of Amyris. "We plan to continue building on our position as the leading synthetic biology company by continuing to deliver the highest purity and most sustainably sourced ingredients for the health, beauty and flavor and fragrance industries. Our brands are delivering the leading products in their respective categories and this is helping us deliver an excellent quarter. We expect to have our financing needs behind us early in 2020 and a strong year of profitable growth."
